Report Sections

See All Reports

  • HP:0010535: Sleep apnea
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0010535: Sleep apnea

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (8)


    Name (Synonyms) Correlation
    drug573 Buspirone + PAP therapy Wiki 0.50
    drug3146 Sleep Education Wiki 0.50
    drug1962 Maltodextrin Wiki 0.50
    Name (Synonyms) Correlation
    drug1493 Home Sleep Apnea Testing or In-hospital Polysomnography Wiki 0.50
    drug3759 Zolpidem + PAP therapy Wiki 0.50
    drug585 CBT-OSA Wiki 0.50
    drug162 Acetazolamide + supplemental oxygen + PAP therapy Wiki 0.50
    drug537 Bovine Lactoferrin Wiki 0.50

    Correlated MeSH Terms (9)


    Name (Synonyms) Correlation
    D012891 Sleep Apnea, NIH 1.00
    D020181 Sleep Apnea, Obstructive NIH 0.87
    D020182 Sleep Apnea, Central NIH 0.50
    Name (Synonyms) Correlation
    D001049 Apnea NIH 0.50
    D053120 Respiratory Aspiration NIH 0.14
    D040921 Stress Disorders, Traumatic NIH 0.09
    D013313 Stress Disorders, Post-Traumatic NIH 0.09
    D013577 Syndrome NIH 0.05
    D011014 Pneumonia NIH 0.03

    Correlated HPO Terms (4)


    Name (Synonyms) Correlation
    HP:0002870 Obstructive sleep apnea HPO 0.87
    HP:0002104 Apnea HPO 0.50
    HP:0002871 Central apnea HPO 0.50
    Name (Synonyms) Correlation
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD

    Approximately 20 million Americans suffer from Obstructive Sleep Apnea (OSA) creating risks for major health problems, including dementia, heart attack, and stroke. Obesity, a growing problem for Americans and Veterans alike, is the greatest risk factor for the development of OSA. Male gender and smoking, other OSA risk factors, are common in Veterans. Given the high comorbidity of these risk factors in Veterans, OSA presents a significant health burden to Veterans. The investigators' prior work provides evidence that OSA occurs in up to 69% of Vietnam-era Veterans with PTSD. OSA is easily treated; however, 15-30% of OSA patients are non-compliant with continuous positive airway pressure (CPAP), the standard OSA treatment. The proposed research aims to facilitate adherence to CPAP treatment by testing a novel cognitive-behavioral therapy intervention in Veterans with PTSD. If successful, it may represent an approach that could be applied to the rehabilitation of other chronic conditions with similar barriers to care.

    NCT02641496
    Conditions
    1. Obstructive Sleep Apnea
    2. PTSD
    3. Posttraumatic Stress Disorder
    Interventions
    1. Behavioral: CBT-OSA
    2. Behavioral: Sleep Education
    MeSH:Sleep Apnea Syndromes Sleep Apnea, Obstructive Stress Disorders, Traumatic Stress Disorders, Post-Traumatic
    HPO:Obstructive sleep apnea Sleep apnea

    Primary Outcomes

    Description: The CPAP machine will measure the number of hours that the CPAP mask is on the participant's face and in use.

    Measure: Time in hours of "mask-on" CPAP usage per night

    Time: 1 year

    Secondary Outcomes

    Description: Effect of CBT on Self-reported Everyday Activities, Mood and Quality of Life. The investigators hypothesize that after initiating CPAP treatment, Veterans in the CBT-OSA group will report more improvement in the ease of performing everyday activities compared to that reported by those in the Education group.

    Measure: Functional Outcomes of Sleep Questionnaire (FOSQ)

    Time: 1 year

    Description: Effect of CBT on Cognitive Outcomes. The CBT-OSA group will have better cognitive outcomes than the Education group over time. The California Verbal Learning Test-II, Delayed Recall Score is the cognitive outcome measure.

    Measure: California Verbal Learning Test, Second Edition (CVLT-II)

    Time: 1 year

    Description: Effect of CBT on PTSD. The CBT-OSA group will have fewer PTSD symptoms than the Education group over time. The PTSD Checklist for DSM-5 (PCL-5) will be the PTSD outcome measure.

    Measure: PTSD Checklist for DSM-5 (PCL-5)

    Time: 1 year
    2 Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment

    Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

    NCT04118387
    Conditions
    1. Sleep Disordered Breathing
    2. Able Bodied
    Interventions
    1. Drug: Acetazolamide + supplemental oxygen + PAP therapy
    2. Drug: Zolpidem + PAP therapy
    3. Drug: Buspirone + PAP therapy
    MeSH:Sleep Apnea Syndromes Respiratory Aspiration Sleep Apnea, Central
    HPO:Central apnea Central sleep apnea Sleep apnea

    Primary Outcomes

    Description: CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.

    Measure: CO2 reserve

    Time: 120 days

    Description: Central apnea indices is used to indicate the severity of central sleep apnea

    Measure: Central apnea indices

    Time: 120 days

    Secondary Outcomes

    Description: Controller gain is a ventilatory response to changes in end-tidal PCO2

    Measure: Controller gain

    Time: 120 days

    Description: Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating CO2.

    Measure: Plant gain

    Time: 120 days

    Description: This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.

    Measure: Carotid body function

    Time: 120 days

    Description: Peripheral chemoreflex sensitivity is measured either via brief hypoxia or a single breath of CO2.

    Measure: Peripheral chemoreflex sensitivity

    Time: 120 days

    Description: The nadir pressure in the upper airway (supra-glottic pressure) prior to the occurrence of an arousal.

    Measure: Respiratory arousal threshold

    Time: 120 days

    Description: To assess breathing stability, the investigators will measure % stable breathing using minute ventilation (VE) and tidal volume (VT) coefficient of variation as indices of breathing instability.

    Measure: % stable breathing

    Time: 120 days
    3 Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study

    Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.

    NCT04363333
    Conditions
    1. COVID
    2. Obstructive Sleep Apnea
    3. Pneumonia
    Interventions
    1. Diagnostic Test: Home Sleep Apnea Testing or In-hospital Polysomnography
    MeSH:Apnea Sleep Apnea Syndromes Pneumonia Sleep Apnea, Obstructive
    HPO:Apnea Obstructive sleep apnea Pneumonia Sleep apnea

    Primary Outcomes

    Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

    Measure: The rate of clinical improvement

    Time: 7 days

    Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

    Measure: The rate of clinical improvement

    Time: 14 days

    Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

    Measure: The rate of clinical improvement

    Time: 21 days

    Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

    Measure: The rate of clinical improvement

    Time: 28 days

    Secondary Outcomes

    Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality

    Measure: Clinical status - improvement

    Time: 7, 14, 21, 28 days

    Description: Defined as an increase in category on a 7-category ordinal scale from admission

    Measure: Clinical status - worsening

    Time: 7, 14, 21, 28 days

    Other Outcomes

    Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.

    Measure: Long-term outcomes

    Time: 4-6 months after the initial hospital admission
    4 Evaluation of Physical Activity Level and Sleep Quality in Patients With Obstructive Sleep Apnea Syndrome During Covid-19 Pandemic

    As long as the people stay at home because of the Covid 19 outbreak, the investigators assume that the sleep quality of OUAS patients, like everyone else, and the sleep quality of COVID-19 outbreak are reduced due to anxiety and anxiety in people. In addition, we assume that sleep quality and physical activity level are related to health literacy level and fear of movement (kinesiophobia). In this study; the investigators aimed to determine how patients are affected by this process by evaluating sleep quality, physical activity, fear of movement and health literacy in OSAS patients during our stay in the COVID-19 outbreak.

    NCT04451993
    Conditions
    1. Obstructive Sleep Apnea-hypopnea Syndrome
    MeSH:Sleep Apnea Syndromes Sleep Apnea, Obstructive Syndrome
    HPO:Obstructive sleep apnea Sleep apnea

    Primary Outcomes

    Description: International Physical Activity Questionnaire/ In activity-specific scoring, walking under the heading of the fields is calculated by the sum of the moderate intensity activity and intensive activity in itself. From these calculations, a score is obtained in MET-minutes. There are 3 categories of physical activity level classification. Physical activity levels are classified as physically inactive (inactive), low level of physical activity (minimally active) and sufficient level of physical activity (very active)

    Measure: Physical Activity

    Time: 1 day

    Description: The Pittsburgh Sleep Quality Index

    Measure: Sleep Quality

    Time: 1 day

    Secondary Outcomes

    Description: In order to measure the general sleepiness of people during the day, it was evaluated with a standard questionnaire, which is defined as Epworth sleepiness scale (EUS) and consists of 8 questions. The answers for each question are scored between 0 and 3 and the total score is obtained. The score obtained above 10 in EUS has high sensitivity and specificity for daytime sleepiness.

    Measure: Daytime Sleepiness

    Time: 1 day

    Description: Tampa Kinesiophobia Scale (TKS)The person gets a total score between 17-68. The high score on the scale indicates that kinesiophobia is also high

    Measure: Fear of movement

    Time: 1 day

    Description: Translated into Turkish TURKEY health literacy SCALE-32 (Tsoy-32) will be used. It was used to evaluate the literacy rates of individuals over the age of 15. 0 indicates the lowest health literacy and 50 indicates the highest health literacy.

    Measure: Health literacy

    Time: 1 day

    Other Outcomes

    Description: In the human circadian rhythm, the Morning Morning-Evening Survey (SAA) form was used, which determined morning and evening types.

    Measure: Circadian rhythm evaluation

    Time: 1 day

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook